Contact
Please use this form to send email to PR contact of this press release:
AriBio Announces Completion of Dosing in POLARIS-AD Global Phase 3 Trial of AR1001 for Early Alzheimer’s Disease
TO:
Tanya Xi, MD, PHD, MBA
AriBio Co., Ltd.